CMML

16 registered clinical trials studyying CMML — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML) NCT06950034	Solu Therapeutics, Inc	Phase 1
Active Not Recruiting	GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG NCT05153226	DKMS gemeinnützige GmbH	Phase 3
Active Not Recruiting	A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML NCT04730258	Treadwell Therapeutics, Inc	Phase 1 / Phase 2
Active Not Recruiting	Pilot Study of CC 486 (Oral Azacitidine) Plus BSC as Maintenance After sc Azacitidine in Elderly HR-IPSS-R MDS NCT04806906	University of Florence	Phase 2
Unknown	A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS NCT04358393	Ascentage Pharma Group Inc.	Phase 1 / Phase 2
Completed	IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML NCT04372433	Immune-Onc Therapeutics	Phase 1
Completed	Haplo Peripheral Blood Sct In GVHD Prevention NCT04473911	Zachariah Michael DeFilipp	Phase 1
Completed	Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in P NCT04139434	Newave Pharmaceutical Inc	Phase 1
Active Not Recruiting	Efficacy and Safety of HMAs Combined With Venetoclax Versus HMAs Alone in ND Int-and H-risk MDS or CMML NCT07318662	Guangdong Provincial People's Hospital	—
Completed	Ascorbic Acid Levels in MDS, AML, and CMML Patients NCT03526666	Van Andel Research Institute	—
Completed	Reduced Intensity Conditioning Transplant Using Haploidentical Donors NCT02581007	Northside Hospital, Inc.	Phase 2
Terminated	A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations NCT02418000	Spirita Oncology, LLC	Phase 1 / Phase 2
Completed	A Study of Eltrombopag in Patients With CMML and Thrombocytopenia NCT02323178	Groupe Francophone des Myelodysplasies	Phase 1 / Phase 2
Completed	Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies NCT02193958	Fujifilm Pharmaceuticals U.S.A., Inc.	Phase 1 / Phase 2
Completed	SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) NCT01261312	Astex Pharmaceuticals, Inc.	Phase 1 / Phase 2
Completed	Non Interventional Study on Iron Toxicity After First Allo-transplant in MDS/CMML NCT06267898	European Society for Blood and Marrow Transplantation	—